In the last year, we have witnessed major advancements in the oligonucleotide, peptide, mRNA and gene edited therapeutics industry, particularly around mRNA vaccines and therapeutics in response to the pandemic.
However, what unique struggles have occurred in projects over the last year and what major changes have occurred in the industry as a whole?
In February 2021, we conducted a global survey of professionals in the sector to find out how organizations are now working and what key strategies may have changed as a result of the COVID-19 pandemic. This report reveals the story so far, including the biggest challenges, advantages and transitions faced across research, development, drug delivery and partnering - read or download it here or by clicking on the image above.
- 45% of respondents said that their company’s partnering and licensing activities had increased since the COVID-19 pandemic began
- 44% of respondents said that their organizations were carrying out work related to COVID-19
- Delivery systems are still the biggest growth area for technology in the field
- Anti-viral systems are now the second most common target for research and development in the industry behind solid tumor oncology